Alberch, PO, Soler, A, Téllez, L, Carrión, JA, Alvarado-Tapias, E, Ferrusquía, JA, Lens, S, Guerrero, A, Falgà, MA, Vizcarra, P, Orts, L, Perez, V, Shalaby, S, Baiges, A, Turon, F, García-Pagán, JC, García-Criado, MA, Hernández-Gea, V. Evaluation of portal hemodynamics after etiological factor removal and persistence of varices in patients with an HVPG <10 mmHg and NITs within the grey zone. JOURNAL OF HEPATOLOGY. 2024; 80DOI:. PMID:. IF:33.000(Q1/1D).

Ballester, MP, Laue, T, Meoli, L, Uson, E, Mutschler, F, Grabitz, C, McLin, V, D'Antiga, L, Pujadas, M, Carvalho-Gomes, A, Sahuco, I, Bono, A, D'Amico, F, Viganò, R, Sempere, ED, Tormo, B, Inglese, E, Martinez, D, Riva, A, Sharma, R, Tsou, HLP, Harris, N, Broekhoven, A, Kikkert, M, Morales, S, Myeni, S, Barciela, MR, Palom, A, Zeni, N, Brocca, A, Cussigh, A, Cmet, S, Escudero-García, D, Stocco, M, Natola, L, Ieluzzi, D, Paon, V, Sangiovanni, A, Farina, E, Di Benedetto, C, Sanchez-Torrijos, YM, Valera, AL, Roman, E, Sanchez, E, Sánchez-Aldehuelo, R, López-Cardona, J, Canas-Perez, I, Jackson, C, Jeyanesan, D, Morocho, AE, Di Cola, S, Lapenna, L, Zaccherini, G, Bongiovanni, D, Zanaga, P, Sayaf, K, Hossain, S, Crespo, J, Robles-Díaz, M, Madejón, A, Degroote, H, Fernández, J, Korenjak, M, Verhelst, X, Garcia-Samaniego, FJ, Andrade, RJ, Iruzubieta, P, Wright, G, Caraceni, P, Merli, M, Patel, VC, Gander, A, Albillos, A, Soriano, G, Donato, MF, Sacerdoti, D, Toniutto, P, Buti, M, Duvoux, C, Grossi, PA, Berg, T, Polak, W, Puoti, M, Bosch, A, Belli, LS, Burra, P, Russo, FP, Coenraad, M, Panero, JLC, Perricone, G, Chokshi, S, Berenguer, M, Clària, J, Moreau, R, Arroyo, V, Angeli, P, Sanchez, C, Ampuero, J, Piano, S, Nicastro, E. Paediatric solid organ transplant recipients (SOTR) demonstrate greater serological response to initial SARS-CoV-2 vaccination than adult SOTR, and comparable rates of antibody degradation. JOURNAL OF HEPATOLOGY. 2024; 80DOI:. PMID:. IF:33.000(Q1/1D).

Molero, X, Ayuso, JR, Balsells, J, Boadas, J, Busquets, J, Casteras, A, Concepcion, M, Cuatrecasas, M, Esparrach, GF, Fort, E, Borobia, FG, Gines, A, Ilzarbe, L, Loras, C, Masachs, M, Merino, X, Olsina, JJ, Puig-Divi, V, Salord, S, Serrano, T, Vaquero, EC. Chronic pancreatitis for the clinician: complications and special forms of the disease. Interdisciplinary position paper of the Catalan Society of Digestology (SCD) and the Catalan Pancreatic Society (SCPanc). Minerva Gastroenterology. 2024; 70(2)DOI:10.23736/S2724-5985.22.03127-8. PMID:35262306. IF:1.500(Q4/8D).

Calm, A, Calafat, M, González-Muñoza, C, Cañete, F, Roig, C, Mañosa, M, García-Planella, E, Domènech, E. Incidence of herpes zoster in patients with inflammatory bowel disease. Gastroenterologia y Hepatologia. 2024; 47(6)DOI:10.1016/j.gastrohep.2024.01.011. PMID:38316174. IF:1.900(Q3/7D).

Millan-Billi, P, Castellví, I, Martinez-Martinez, L, Mariscal, A, Barril, S, D'Alessandro, M, Franquet, T, Castillo, D. Diagnostic Value of Krebs von den Lungen (KL-6) for Interstitial Lung Disease: A European Prospective Cohort. ARCHIVOS DE BRONCONEUMOLOGIA. 2024; 60(6)DOI:10.1016/j.arbres.2024.03.028. PMID:38644152. IF:9.200(Q1/1D).

de la Rosa-Carrillo, D, de Granda-Orive, JI, Cáceres, LD, Pereyra, FG, Moreno, BR, Martínez-Garcia, MA, Suárez-Cuartin, G. The impact of smoking on bronchiectasis and its comorbidities. Expert Review of Respiratory Medicine. 2024; 18(5)DOI:10.1080/17476348.2024.2369716. PMID:38888096. IF:2.700(Q2/5D).

Lugogo, NL, Heffler, E, Plaza,, Hilberg, O, Xia, C, Nash, S, Pandit-Abid, N, Jacob-Nara, JA, Sacks, H, Rowe, PJ, Deniz, Y, Hardin, M, Reed, C, Soler, X. BASELINE CHARACTERISTICS OF PATIENTS WITH ASTHMA AND PRIOR ORAL SYSTEMIC CORTICOSTEROID USE INITIATING DUPILUMAB IN A REAL-WORLD REGISTRY (RAPID). VALUE IN HEALTH. 2024; 27(6)DOI:. PMID:. IF:6.000(Q1/1D).

Suades, R, Padró, T, Domingo, P, Greco, MF, Benincasa, G, Greco, S, Madè, A, Ranucci, M, Devaux, Y, Martelli, F, Badimon, L. Blood immune and endothelial cell-released extracellular vesicle changes relate to COVID-19 mortality in hospitalized patients. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).

Tibau, A, Kesselheim, AS. Global cooperation and early access-clinical outcomes matter. LANCET ONCOLOGY. 2024; 25(6)DOI:10.1016/S1470-2045(24)00210-9. PMID:38754452. IF:35.900(Q1/1D).

Gately, L, Mesía, C, Sepúlveda, JM, del Barco, S, Pineda, E, Gironés, R, Fuster, J, Dumas, M, Gill, S, Navarro, LM, Herrero, A, Dowling, A, de las Peñas, R, Vaz, MA, Alonso, M, Lwin, Z, Harrup, R, Peralta, S, Long, A, Perez-Segura, P, Ahern, E, Garate, CO, Wong, M, Campbell, R, Cuff, K, Jennens, R, Gallego, O, Underhill, C, Martinez-Garcia, M, Covela, M, Cooper, A, Brown, S, Rosenthal, M, Torres, J, Collins, IM, Gibbs, P, Balana, C. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). JOURNAL OF NEURO-ONCOLOGY. 2024; 168(2)DOI:10.1007/s11060-024-04668-5. PMID:38630385. IF:3.100(Q2/4D).

Tibau, A, Hwang, TJ, Avorn, J, Kesselheim, AS. Clinical applicability of guideline-recommended molecular targets and genometargeted cancer therapies. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Serda, PC, Cullell, BM, Castet, F, Gatell, AP, Fernandez, PR, Fernandez, J, Nadal, TS, Mateo, FJP, Sorolla, MA, Cajal, TRY. Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/annonc.2024.05.508. PMID:. IF:65.400(Q1/1D).

Reinacher-Schick, AC, Lopez, MR, Alonso-Orduña, V, Lopez-Bravo, DP, Vergauwe, P, Tannapfel, A, Silveira, AB, Schlombs, K, Young, P, He, Y, Henn, H, Manning, L, Preussner, L, Mueller, F, Sahin, U, Türeci, O. Preliminary results correlating post-operative ctDNA status with disease-free survival in patients with stage II (high risk)/III colorectal cancer in the BNT000-001 epidemiology study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Schreurs, MAC, Cajal, TRY, Adank, MA, Collée, JM, Hollestelle, A, van Rooij, J, Schmidt, MK, Hooning, MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families (vol 73, 103611, 2024). BREAST. 2024; 75DOI:10.1016/j.breast.2024.103723. PMID:. IF:7.900(Q1/1D).

Aggarwal, C, Martinez-Marti, A, Majem, M, Barlesi, F, Carcereny, E, Chu, QS, Monnet, I, Sanchez, A, Dakhil, SR, Camidge, DR, Pillet, M, Brown, M, Dowson, A, Cooper, ZA, Kumar, R, Herbst, RS. Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Berciano-Guerrero, MA, Perez-Ruiz, E, Couselo, EM, Manzano, JL, Cerezuela-Fuentes, P, de Miguel, PA, Soria, A, Castaño, AG, Crespo, G, Puértolas, T, De La Rosa, CA, Sanz, LG, Castro, RL, Espinosa, E, Lecumberri, MJ, Majem, M, Martinez, JM, Bellido, L, Fernández-Morales, LA, Martin-Algarra, S. Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Martelli, V, Barrull, JV, Rodriguez, CF, Alfonso, PG, Paez, D, Gibert, J, Alonso, V, España, MAG, Vivas, CS, Ogalla, GD, Fernandez, MEE, Garcia-Carbonero, R, Monteagudo, RF, Mozo, JLM, Losa, F, Paricio, BB, Tabernero, J, Soler, RS, Aguilar, EA, Viladot, CM. Circulating tumor DNA (ctDNA) to detect acquired resistance to first-line (1L) treatment of RASWT metastatic colorectal cancer (mCRC): Insights from the PLATFORM-B study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.121. PMID:. IF:65.400(Q1/1D).

Taieb, J, Fakih, M, Salvatore, L, Esaki, T, Modest, DP, Paez, D, Karamouzis, MV, Ruiz, E, Kim, TW, Kuboki, Y, Meriggi, FA, Cunningham, D, Yeh, KH, Cremolini, C, Wang, J, Tran, Q, Chao, J, Chen, Z, Pietrantonio, F. Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.043. PMID:. IF:65.400(Q1/1D).

John, T, Grohe, C, Goldman, JW, Kato, T, Laktionov, KK, Bonanno, L, Tiseo, M, Majem, M, Domine, M, Ahn, MJ, Perol, M, Hartmaier, R, Robichaux, J, Bhetariya, P, Markovets, A, Rukazenkov, Y, Muldoon, C, Herbst, RS, Tsuboi, M, Wu, YL. Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

González-Lopez, JA, Sebio, A, Hindi, N, Jimenez, M, Villarejo-Campos, P, Martin-Broto, J, Díaz-Beveridge, R, Castellanos, JFO, Andújar, RL, Alvarez, RA, Asencio, JM, Serrano, C, Conde, NR, Boix, SC, Gimenez-Salinas, LK, Garcia, JAT, Campos, AP, Lopera, E, Bertran, J, Pousa, AL. First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).